---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-007139"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:27:49.813470+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# bioAffinity Technologies publishes CyPath Lung case study showing 92% sensitivity in small nodules

## Summary
- CyPath Lung test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy for detecting lung cancer in nodules <2 cm.
- Case study: 59-year-old with 30-year smoking history, COPD, multiple Lung-RADS 3 nodules; negative CyPath result.
- Negative result allowed continued CT surveillance; follow-up CT showed stable nodules, avoiding invasive procedures.
- Company markets test as LDT; case study reinforces clinical utility for reducing anxiety and supporting treatment decisions.

## SEC filing metadata
- accession: 0001493152-26-007139
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226007139/0001493152-26-007139-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226007139/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-007139
- JSON: https://secwatch.observer/filing/0001493152-26-007139.json
- Plain text: https://secwatch.observer/filing/0001493152-26-007139.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.